Clinical Studies

PreciseOnco’s collaborative network spans the entire spectrum of oncological care from pre-clinical development to clinical studies. This effort aims to ensure that the 2.7 million individuals diagnosed with cancer annually in Europe gain access to safer, faster, and more affordable treatment options.

VISTA

The clinical study VISTA (Virtual Spectral Imaging for Superior Thermal Ablation Guidance) will be conducted at UMCU in collaboration with partner sites in LUMC and APHP. It aims to evaluate the effectiveness of spectral CBCT in overcoming the limitations of conventional CT and CBCT in thermal ablation procedures. The study will assess its ability to enhance lesion visualization, improve tumor boundary delineation, and reduce motion artifacts. This will ultimately lead to better treatment precision, reduced complications, and improved patient outcomes during interventional procedures for liver and kidney tumors. The study also aims to compare Spectral CBCT to conventional CBCT in terms of image quality, diagnostic confidence, and radiation dose. By addressing these challenges, the study aims to improve the overall safety and success of oncological interventions.

SPOT ON

The clinical study SPORT ON (SPectral angiography-computed tomography to Optimize percutaneous Tumor ablation) aims to evaluate the clinical value of spectral CT imaging in optimizing percutaneous thermal ablation procedures, comparing spectral CT-based tumor visualization, targeting, and margin assessment to conventional CT, with the goal of improving local tumor control and minimizing recurrence rates. It is performed by LUMC, APHP and HCL.

HORA EST HCC2

The clinical study HORA EST HCC 2 (High-precision One-session Robotic Ablation and chemoEmbolisation guided by Spectral computed Tomography in Hepatocellular Carcinoma: a phase II non-randomized study) investigates the efficacy, safety, and workflow benefits of combining thermal ablation with adjuvant segmental TACE in a single session, with the aim of improving patient outcomes, reducing procedure time, and optimizing oncological care through the use of AngioCT. It is performed by the collaboration between LUMC, APHP, and HCL.

SPECTRA L

The clinical study SPECTRA L (Spectral Performance Evaluation of a CT-Equipped Therapeutic Radiology Angio Suite in Liver), conducted in collaboration with APHP, LUMC, and HCL, aims to evaluate the clinical utility of integrating multidetector spectral CT into the Angio Suite for TACE patients. The study will assess whether spectral CT, using advanced features like iodine quantification and material decomposition, can predict treatment response at the end of the intervention and potentially enhance the precision of tumor assessment.

LASER

The clinical study LASER (Locoregional therApies Spectral Evaluation of Responses), led by HCL with participation from LUMC, APHP, and UMCU, seeks to identify spectral CT markers for predicting treatment success in thermoablation, electrochemotherapy, and irreversible electroporation for liver, kidney, nodal, lung, and musculoskeletal tumors. The study will examine whether spectral imaging can improve visualization, guide treatment adaptation, and predict post-procedural outcomes, particularly in real-time tumor monitoring.